meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
antibody–drug conjugate
enfortumab vedotin-ejfv
sacituzumab govitecan
gene alteration target therapy
FGFR (2/3) gene alteration targeted therapy
erdafitinib
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus SoC
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
durvalumab plus BCG
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus BCG
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
poly ADP-ribose polymerase (PARP) inhibitor
olaparib
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs pembrolizumab based treatment
vs pembrolizumab alone
vs Immunostimulant
vs vaccine
vs BCG
vs non active control
vs BSC
vs no additional treatment
vs no control (uncontrolled study)
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network